288 related articles for article (PubMed ID: 18808096)
1. Combining ligand-based pharmacophore modeling, quantitative structure-activity relationship analysis and in silico screening for the discovery of new potent hormone sensitive lipase inhibitors.
Taha MO; Dahabiyeh LA; Bustanji Y; Zalloum H; Saleh S
J Med Chem; 2008 Oct; 51(20):6478-94. PubMed ID: 18808096
[TBL] [Abstract][Full Text] [Related]
2. Discovery of new MurF inhibitors via pharmacophore modeling and QSAR analysis followed by in-silico screening.
Taha MO; Atallah N; Al-Bakri AG; Paradis-Bleau C; Zalloum H; Younis KS; Levesque RC
Bioorg Med Chem; 2008 Feb; 16(3):1218-35. PubMed ID: 17988876
[TBL] [Abstract][Full Text] [Related]
3. Elaborate ligand-based modeling reveals new nanomolar heat shock protein 90α inhibitors.
Al-Sha'er MA; Taha MO
J Chem Inf Model; 2010 Sep; 50(9):1706-23. PubMed ID: 20831219
[TBL] [Abstract][Full Text] [Related]
4. Pharmacophore modeling, quantitative structure-activity relationship analysis, and shape-complemented in silico screening allow access to novel influenza neuraminidase inhibitors.
Abu Hammad AM; Taha MO
J Chem Inf Model; 2009 Apr; 49(4):978-96. PubMed ID: 19341295
[TBL] [Abstract][Full Text] [Related]
5. Pharmacophore and QSAR modeling of estrogen receptor beta ligands and subsequent validation and in silico search for new hits.
Taha MO; Tarairah M; Zalloum H; Abu-Sheikha G
J Mol Graph Model; 2010 Jan; 28(5):383-400. PubMed ID: 19850503
[TBL] [Abstract][Full Text] [Related]
6. Elaborate ligand-based modeling and subsequent synthetic exploration unveil new nanomolar Ca2+/calmodulin-dependent protein kinase II inhibitory leads.
Shahin R; Taha MO
Bioorg Med Chem; 2012 Jan; 20(1):377-400. PubMed ID: 22112539
[TBL] [Abstract][Full Text] [Related]
7. Extensive ligand-based modeling and in silico screening reveal nanomolar inducible nitric oxide synthase (iNOS) inhibitors.
Suaifan GA; Shehadehh M; Al-Ijel H; Taha MO
J Mol Graph Model; 2012 Jul; 37():1-26. PubMed ID: 22609742
[TBL] [Abstract][Full Text] [Related]
8. Discovery of DPP IV inhibitors by pharmacophore modeling and QSAR analysis followed by in silico screening.
Al-Masri IM; Mohammad MK; Taha MO
ChemMedChem; 2008 Nov; 3(11):1763-79. PubMed ID: 18989859
[TBL] [Abstract][Full Text] [Related]
9. Discovery of new potent human protein tyrosine phosphatase inhibitors via pharmacophore and QSAR analysis followed by in silico screening.
Taha MO; Bustanji Y; Al-Bakri AG; Yousef AM; Zalloum WA; Al-Masri IM; Atallah N
J Mol Graph Model; 2007 Mar; 25(6):870-84. PubMed ID: 17035054
[TBL] [Abstract][Full Text] [Related]
10. Discovery of new cholesteryl ester transfer protein inhibitors via ligand-based pharmacophore modeling and QSAR analysis followed by synthetic exploration.
Abu Khalaf R; Abu Sheikha G; Bustanji Y; Taha MO
Eur J Med Chem; 2010 Apr; 45(4):1598-617. PubMed ID: 20116902
[TBL] [Abstract][Full Text] [Related]
11. Elaborate ligand-based pharmacophore exploration and QSAR analysis guide the synthesis of novel pyridinium-based potent beta-secretase inhibitory leads.
Al-Nadaf A; Abu Sheikha G; Taha MO
Bioorg Med Chem; 2010 May; 18(9):3088-115. PubMed ID: 20378363
[TBL] [Abstract][Full Text] [Related]
12. Discovery of new β-D-galactosidase inhibitors via pharmacophore modeling and QSAR analysis followed by in silico screening.
Abdula AM; Khalaf RA; Mubarak MS; Taha MO
J Comput Chem; 2011 Feb; 32(3):463-82. PubMed ID: 20730780
[TBL] [Abstract][Full Text] [Related]
13. Discovery of new renin inhibitory leads via sequential pharmacophore modeling, QSAR analysis, in silico screening and in vitro evaluation.
Al-Nadaf AH; Taha MO
J Mol Graph Model; 2011 Apr; 29(6):843-64. PubMed ID: 21376648
[TBL] [Abstract][Full Text] [Related]
14. Discovery of new nanomolar peroxisome proliferator-activated receptor γ activators via elaborate ligand-based modeling.
Al-Najjar BO; Wahab HA; Tengku Muhammad TS; Shu-Chien AC; Ahmad Noruddin NA; Taha MO
Eur J Med Chem; 2011 Jun; 46(6):2513-29. PubMed ID: 21482446
[TBL] [Abstract][Full Text] [Related]
15. Structure-based approach to pharmacophore identification, in silico screening, and three-dimensional quantitative structure-activity relationship studies for inhibitors of Trypanosoma cruzi dihydrofolate reductase function.
Schormann N; Senkovich O; Walker K; Wright DL; Anderson AC; Rosowsky A; Ananthan S; Shinkre B; Velu S; Chattopadhyay D
Proteins; 2008 Dec; 73(4):889-901. PubMed ID: 18536013
[TBL] [Abstract][Full Text] [Related]
16. Discovery of new antifungal leads via pharmacophore modeling and QSAR analysis of fungal N-myristoyl transferase inhibitors followed by in silico screening.
Taha MO; Qandil AM; Al-Haraznah T; Khalaf RA; Zalloum H; Al-Bakri AG
Chem Biol Drug Des; 2011 Sep; 78(3):391-407. PubMed ID: 21679375
[TBL] [Abstract][Full Text] [Related]
17. Pharmacophore modeling, quantitative structure-activity relationship analysis, and in silico screening reveal potent glycogen synthase kinase-3beta inhibitory activities for cimetidine, hydroxychloroquine, and gemifloxacin.
Taha MO; Bustanji Y; Al-Ghussein MA; Mohammad M; Zalloum H; Al-Masri IM; Atallah N
J Med Chem; 2008 Apr; 51(7):2062-77. PubMed ID: 18324764
[TBL] [Abstract][Full Text] [Related]
18. Novel inhibitors of human histone deacetylase (HDAC) identified by QSAR modeling of known inhibitors, virtual screening, and experimental validation.
Tang H; Wang XS; Huang XP; Roth BL; Butler KV; Kozikowski AP; Jung M; Tropsha A
J Chem Inf Model; 2009 Feb; 49(2):461-76. PubMed ID: 19182860
[TBL] [Abstract][Full Text] [Related]
19. Elaborate ligand-based modeling reveal new submicromolar Rho kinase inhibitors.
Shahin R; Alqtaishat S; Taha MO
J Comput Aided Mol Des; 2012 Feb; 26(2):249-66. PubMed ID: 22167443
[TBL] [Abstract][Full Text] [Related]
20. Ligand-based designing, in silico screening, and biological evaluation of new potent fructose-1,6-bisphosphatase (FBPase) inhibitors.
Tayyem RF; Zalloum HM; Elmaghrabi MR; Yousef AM; Mubarak MS
Eur J Med Chem; 2012 Oct; 56():70-95. PubMed ID: 22960695
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
